The Stockholm Stock Exchange opened Monday's session with a slight decline, as market participants remain focused on geopolitical developments in the Middle East. In corporate news, Diamyd Medical is cratering following a failed Phase 3 study, while Transtema is under pressure after announcing a rights issue.

As of 09:15 CET, the blue-chip OMXS30 index was down 0.22 percent at 2,857.60. Adjusted for dividends, the OMXS30 index traded 0.19 percent lower. Shares worth approximately 1.2 billion kronor changed hands on the Stockholm bourse.

Energy was the top-performing major industrial sector, gaining 2.1 percent. Conversely, healthcare lagged at the bottom of the pile, shedding 0.6 percent.

Among the leading constituents of the OMXS30 index, Evolution rose 2.1 percent, while H&M B gained 0.9 percent. Lifco B posted the weakest performance, falling 1.2 percent, while Industrivärden C retreated 1.0 percent.

Engineering group Sandvik is launching the second phase of its restructuring program within the Machining business area. The measures are part of a broader initiative to bolster efficiency and margins through 2030. This new phase is expected to generate annual savings of 105 million kronor, fully realized by 2027. One-off costs amount to 315 million kronor and include a reduction of 130 positions. The stock is down 0.2 percent.

Diabetes research firm Diamyd Medical reported negative interim results from its Phase 3 Diagnode-3 study. The interim analysis, which included 174 of 321 participants, failed to show statistical significance for the primary efficacy endpoint. Furthermore, the study did not meet the predefined criteria required to support its continuation. "This outcome is very unexpected and inconsistent with the overall picture from previous data," commented CEO Ulf Hannelius. The stock is plunging 90 percent.

The board of IT infrastructure company Transtema has resolved to carry out a rights issue of 40.3 million kronor before transaction costs. The rights issue is fully covered by subscription and guarantee commitments. The stock is tumbling 35 percent.

TF Bank's British subsidiary, TFBN Services, has been granted authorization by the Financial Conduct Authority (FCA) to conduct consumer credit activities and offer payment services in the UK. The stock is losing 3.9 percent.

Infranets company Netel's subsidiary, Nett-Tjenester, has signed a framework agreement with Norway's Glitre Nett worth up to 300 million Norwegian kroner. The agreement covers a new geographical area and concerns services within the regional grid. The stock is up 1.9 percent.

Dagens Industri has issued a buy recommendation for Mildef, sending the shares up 11.2 percent.

Pareto Securities has initiated coverage of Elekta with a buy rating, prompting the stock to rise 0.8 percent.

SEB has scrapped its buy recommendation for Hexatronic, downgrading the stock to hold. The shares are sinking 9.2 percent.

Bank of America has pulled its buy rating on Electrolux, downgrading the stock to underperform. The shares are falling 5.4 percent.

Kempen has upgraded its ratings for real estate companies SLP and Sagax to buy and neutral, respectively. SLP is down 0.3 percent, while Sagax is up 0.3 percent.